1. American Cancer Society . Facts & Figures 2021. American Cancer Society Atlanta, Ga [Internet]. 2021 [cited 2021 Aug 16]; Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf.
Google Scholar2. Kirby, R . The role of PSA in detection and management of prostate cancer. Practitioner 2016; 260: 17–21. 3.
Google Scholar | Medline3. Feng, Q, He, B. Androgen receptor signaling in the development of castration-resistant prostate cancer. Front Oncol 2019; 9: 858.
Google Scholar | Crossref | Medline4. Auchus, RJ, Yu, MK, Nguyen, S, et al. Use of prednisone With Abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 2014; 19: 1231–1240.
Google Scholar | Crossref | Medline | ISI5. European Medicines Agency (EMA) . Zytiga. European Public Assessment Report (EPAR) - Product information [Internet]. [cited 2021 Aug 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga.
Google Scholar6. Walsh, PC, Siiteri, PK. Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate. J Urol 1975; 114: 254–256.
Google Scholar | Crossref | Medline7. Sundar, S, Dickinson, PD. Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ Case Rep 2012; 201228: bcr1120115238.
Google Scholar8. Horn, JR, Hansten, PD, Chan, L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41: 674–680.
Google Scholar | SAGE Journals | ISI9. Brown, J, Farquhar, C, Lee, O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2009; Apr 15: CD000194.
Google Scholar10. Angus, L, Leemaqz, S, Ooi, O, et al. Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy. Endocr Connect 2019; 8: 935–940.
Google Scholar | Crossref | Medline11. Beckmann, K, Garmo, H, Lindahl, B, et al. Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer Prostatic Dis 2020; 23: 527–533.
Google Scholar | Crossref | Medline12. Luthy, IA, Begin, DJ, Labrie, F. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (shionogi) cells in culture. J Steroid Biochem 1988; 31: 845–852.
Google Scholar | Crossref | Medline13. Barthelemy, P, Erdmann, E, Duclos, B, et al. Spironolactone: a selective androgen receptor modulator in castration-resistant prostate cancer. J Clin Oncol 2014; 32: 212–212.
Google Scholar | Crossref | Medline14. Flynn, T, Guancial, EA, Kilari, M, et al. Case report: spironolactone withdrawal associated With a dramatic response in a patient With metastatic castrate-resistant prostate cancer. Clin Genitourin Cancer 2017; 15: e95–e97.
Google Scholar | Crossref | Medline15. Dhondt, B, Buelens, S, Van Besien, J, et al. Abiraterone And spironolactone in prostate cancer: a combination to avoid. Acta Clin Belg 2019; 74: 439–444.
Google Scholar | Crossref | Medline16. Lexicomp. Drug interactions . Wolters kluwer clinical drug information. Hudson, Ohio: Lexi-comp, Inc, 2021, [cited August 2021]. Available from: http://online.lexi.com.
Google Scholar17. Micromedex: Drug interactions . Columbia Basin college library ed. [Electronic version]. Greenwood Village, CO: Truven Health Analytics, 2021, Retrieved August 2021 from http://www.micromedexsolutions.com/.
Google Scholar18. Attard, G, Reid, AHM, de Bono, JS. Abiraterone Acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol 2010; 28: e560–e561.
Google Scholar | Crossref | Medline19. Richards, J, Lim, AC, Hay, CW, et al. Interactions of Abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing Abiraterone exposure or combining with MDV3100. Cancer Res 2012; 72: 2176–2182.
Google Scholar | Crossref | Medline | ISI20. Funder, JW, Carey, RM, Mantero, F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889–1916.
Google Scholar | Crossref | Medline | ISI21. Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC) . Journal of Clinical Oncology [Internet]. [cited 2021 Aug 16]. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.5008.
Google Scholar22. Efstathiou, E, Titus, M, Wen, S, et al. Enzalutamide in combination with Abiraterone acetate in bone metastatic castration-resistant prostate cancer patients. Eur Urol Oncol 2020; 3: 119–127.
Google Scholar | Crossref | Medline